Fragment, Modified GRF, Ipamorelin 12mg (Blend) — Premium Synergy Research Peptide

This specialized 12mg synergistic blend combines three highly studied peptides—AOD9604 (GH Fragment 176-191), Modified GRF 1-29 (CJC-1295 no DAC), and Ipamorelin—engineered to investigate multi-pathway growth hormone modulation and lipid metabolism. By combining a selective growth hormone-releasing hormone (GHRH) analog, a selective growth hormone secretagogue receptor (GHSR) agonist, and a lipolytic-targeted GH fragment, this compound provides researchers with a powerful, all-in-one tool for cellular and metabolic study.

• Advanced Tri-Peptide Synergy: Combines three distinct mechanisms of action (GHRH stimulation, GHSR activation, and targeted lipid-pathway modulation) in a single, balanced vial.

• Key Research Areas: Extensively researched for metabolic rate optimization, targeted lipolysis (without affecting blood glucose), muscle tissue repair, and pulsatile growth hormone secretion.

• Purity Guaranteed: $\ge 99\%$ purity of each individual peptide in the blend, verified by HPLC and Mass Spectrometry testing.

• Optimal Stability: Lyophilized powder format ensures maximum compound stability, structural integrity, and precise reconstitution for laboratory assays.

Note: This product is sold strictly as a high-purity research chemical. It is intended solely for laboratory, in vitro, or animal research applications and is not approved for human injection, therapeutic, or diagnostic use.